Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million

Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)

Worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by J&J were USD 4,207 million in the second quarter of 2026.

Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world.

Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.

About Genmab

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines.

For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities.

Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific.

For more information, please visit Genmab.com and follow us on LinkedIn an...